Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Fenofibrate

Aliases
Antara, Fenofibrate 145 mg, Fenofibrate 160mg, Tricor (1 other aliases)
Name
Fenofibrate
INN Name
fenofibrate
FDA Approved
Yes

26 clinical trials

52 organizations

26 indications

6 documents

Indication
Severe Hypertriglyceridemia
Indication
Hypercholesterolemia
Indication
Diabetic Retinopathy
Indication
Inflammatory Bowel Disease
Indication
Breast Cancer
Indication
Primary Biliary Cholangitis
Indication
Diabetes Mellitus
Indication
Type 2
Indication
Klinefelter syndrome
Indication
Neonatal jaundice
Indication
Physiological Hyperbilirubinaemia
Indication
Liver Transplant
Indication
Cervical Intraepithelial Neoplasia
Indication
Cervical Cancer
Indication
Type 2 Diabetes
Indication
Cardiovascular Diseases
Indication
Pharmacogenomic Drug Interaction
Indication
Diabetic Nephropathies
Indication
Neonatal Jaundice
Indication
Hypertriglyceridemia
Indication
Dyslipidemia
Indication
Obesity Associated Disorder
Indication
Primary Biliary Cirrhosis
Indication
Type 1 Diabetes Mellitus
Indication
COVID-19
Indication
Huntington's disease
Clinical trial
A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With a 40-Week, Active-Controlled, Double-Blind Extension to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting Triglyceride Levels ≥500 mg/dL and <2000 mg/dL and Normal Renal Function
Status: Completed, Estimated PCD: 2019-06-24
Clinical trial
A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double--Blind, 12-Week Study With a 40-Week, Active-Controlled, Open-Label Extension to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting Triglyceride Levels ≥500 mg/dL and <2000 mg/dL and Mild or Moderate Renal Impairment
Status: Completed, Estimated PCD: 2019-07-05
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open Label Treatment Period to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
Status: Completed, Estimated PCD: 2021-01-14
Clinical trial
A Randomised Placebo-controlled Trial of Fenofibrate to Prevent Progression of Non-proliferative Retinopathy in Diabetes
Status: Completed, Estimated PCD: 2023-11-17
Clinical trial
Clinical Study to Evaluate the Possible Efficacy of Fenofibrate in Patient With Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2025-02-20
Clinical trial
Clinical Study to Evaluate the Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Fenofibrate in Type 2 Diabetes- Novel Biomarkers and Mechanisms
Status: Completed, Estimated PCD: 2020-03-04
Clinical trial
Interrogating Fatty Acid Metabolism Impairment and Clinical Correlates in Males With Klinefelter Syndrome
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Comparison of Effects of Fenofibrate Adjuvant Therapy Versus Conventional Phototherapy in Treatment of Neonatal Exaggerated Hyperbilirubinemia.
Status: Not yet recruiting, Estimated PCD: 2024-07-01
Clinical trial
Fenofibrate to Prevent Ischemic Cholangiopathy in Donation After Circulatory Death Liver Transplantation (FICsDCD)
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Window of Opportunity Trial of Fenofibrate in Patients With High-grade Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma
Status: Not yet recruiting, Estimated PCD: 2025-01-31
Clinical trial
An Open Label Long-Term Study to Evaluate the Safety and Effectiveness of Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)
Status: Recruiting, Estimated PCD: 2027-04-01
Clinical trial
Physiopathological Study of Genetic Modulation of Cardiovascular Effect of PPAR-Alpha Activation (MAGNETIC-PPARA)
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Repurposing Fenofibrate in Modulating mTOR/NLRP3 Inflammasome in Patients With Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2024-10-20
Clinical trial
A Phase IIa, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease
Status: Completed, Estimated PCD: 2021-08-31
Clinical trial
A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Prophylactic Role of Fenofibrate in Neonatal Jaundice
Status: Completed, Estimated PCD: 2023-11-20
Clinical trial
Safety and Efficacy of Fenofibrate in the Treatment of Pregnant Women With Severe Hypertriglyceridemia
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Fenofibrate Role Against Chemotherapy Induced Peripheral Neurotoxicity in Breast Cancer Patients
Status: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening
Status: Recruiting, Estimated PCD: 2029-04-01
Clinical trial
Efficacy and Safety of Extended Release Niacin-Fenofibrate Combination and Monotherapy for the Treatment of Atherogenic Dyslipidemia in Obese Females
Status: Completed, Estimated PCD: 2015-06-30
Clinical trial
Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis: a Randomized Control Study
Status: Completed, Estimated PCD: 2022-05-06
Clinical trial
Fenofibrate Combined With Ursodeoxycholic Acid in Compensated Cirrhosis Patients With Primary Biliary Cholangitis Who Had an Inadequate Response to Ursodeoxycholic Acid
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomised Trial to Evaluate the Efficacy on Retinopathy and Safety of Fenofibrate in Adults With Type 1 Diabetes. A Multicentre Double-blind Placebo-controlled Study in Australia and Internationally.
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 - Effect of Fenofibrate
Status: Completed, Estimated PCD: 2022-05-10
Document
DailyMed Label: Fenofibrate
Organization
Physicians Total Care, Inc.
Document
DailyMed Label: Fenoglide
Organization
Shore Therapeutics, Inc
Organization
NuCare Pharmaceuticals,Inc.
Organization
A-S Medication Solutions
Organization
Sun Pharmaceutical Industries, Inc.
Organization
Santarus, Inc.
Document
DailyMed Label: Lipofen
Organization
ANI Pharmaceuticals, Inc.
Organization
Oceanside Pharmaceuticals
Organization
Alembic Pharmaceuticals Inc.
Organization
bryant ranch prepack
Organization
Dr. Reddy's Laboratories Inc.
Organization
Denton Pharma, Inc. DBA Northwind Pharmaceuticals
Organization
Mylan Institutional Inc.
Organization
Leading Pharma, LLC
Organization
Proficient Rx LP
Document
DailyMed Label: Antara
Organization
Lupin Pharmaceuticals, Inc.
Organization
American Health Packaging
Organization
Quallent Pharmaceuticals Health LLC
Document
DailyMed Label: Tricor
Organization
AbbVie Inc.
Organization
Amneal Pharmaceuticals of New York LLC
Organization
Austarpharma, LLC
Organization
Laurus Labs Limited
Organization
Golden State Medical Supply, Inc.
Organization
Lifestar Pharma LLC
Organization
CIPLA USA INC.,
Organization
Northwind Pharmaceuticals
Organization
Glenmark Pharmaceuticals Inc., USA
Organization
Alembic Pharmaceuticals Limited
Organization
PD-Rx Pharmaceuticals, Inc.
Organization
Rhodes Pharmaceuticals L.P.
Organization
Apotex Corp.
Organization
Mylan Pharmaceuticals Inc.
Organization
Westminster Pharmaceuticals, LLC
Organization
Creekwood Pharmaceuticals LLC
Organization
Northwind Pharmaceuticals, LLC
Organization
AvPAK
Organization
Ajanta Pharma USA Inc.
Organization
Torrent Pharmaceuticals Limited
Organization
Direct_Rx
Organization
Preferred Pharmaceuticals, Inc.
Document
DailyMed Label: fenofibrate
Organization
Graviti Pharmaceuticals Private Limited
Organization
AvKARE
Organization
Quality Care Products, LLC
Organization
Amneal Pharmaceuticals NY LLC
Organization
REMEDYREPACK INC.
Organization
Preferred Pharmaceuticals Inc. USA
Organization
Aurobindo Pharma Limited
Organization
Cipla USA Inc.
Organization
Major Pharmaceuticals
Organization
St. Mary's Medical Park Pharmacy
Organization
AbbVie Inc.
Organization
Oscient Pharmaceuticals Corporation